Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib plus tislelizumab versus regorafenib alone after acquired resistance to first-line lenvatinib plus immunotherapy in advanced hepatocellular carcinoma
ChiCTR2500103439Phase 4Not yet recruiting
- Sponsor
- Beijing Ditan Hospital
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of regorafenib and tislelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Ditan Hospital. Primary endpoint: Progression-Free Survival. Planned start May 2025; status: not yet recruiting.
02
Drugs
regorafenibtislelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500103439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103439.